Ulcerative Colitis
Inflammatory bowel disease causing ulcers and inflammation in the colon and rectum.
TL;DR
Ulcerative colitis is treated by inducing and maintaining mucosal healing with mesalazine, steroids or biologics. Supplements support nutrition and adjunctive symptom control — they do not maintain remission.
Overview
Ulcerative colitis is chronic inflammation of the colonic mucosa beginning at the rectum and extending proximally in a continuous pattern, distinguishing it from the patchy transmural involvement of Crohn disease. Flares present with bloody diarrhoea, urgency, tenesmus and cramping, and severity is graded by stool frequency, systemic features and inflammatory markers. Treatment follows a clear structure: 5-aminosalicylates for mild to moderate disease, corticosteroids for flare induction only, and thiopurines, biologics or small molecules for maintenance in more active disease. Two things about maintenance are underappreciated. First, adherence to mesalazine substantially reduces both relapse and long-term colorectal cancer risk, which makes stopping it during remission a poor trade. Second, colonoscopic surveillance from eight years after diagnosis is standard because cancer risk rises with disease duration and extent. Nutritional consequences accumulate quietly: iron deficiency from blood loss is near-universal in active disease, and vitamin D deficiency is common. Supplement evidence is genuinely interesting here. Multi-strain probiotic formulations have randomised evidence in inducing remission in mild to moderate disease and in pouchitis prevention after colectomy, which is one of the strongest probiotic indications in medicine. Curcumin as an add-on to mesalazine improved remission rates in a randomised trial. Neither replaces standard therapy.
Common Symptoms
- •Bloody diarrhoea
- •Urgency and tenesmus
- •Lower abdominal cramping
- •Fatigue and anaemia
- •Weight loss in severe disease
- •Joint, eye or skin involvement
Common Causes
- •Immune dysregulation against gut microbiota
- •Genetic susceptibility
- •Epithelial barrier dysfunction
- •Prior enteric infection
- •Antibiotic exposure
- •Environmental and dietary factors
Root Causes
Dysregulated mucosal immune response to gut microbiota in genetically susceptible individuals, impaired colonic epithelial barrier function, reduced short-chain fatty acid availability to colonocytes, prior gastrointestinal infection, and environmental factors including diet and antibiotic exposure.
How It's Diagnosed
Diagnostic Markers
- Faecal calprotectin for mucosal inflammation
- Colonoscopy with biopsy for diagnosis and extent
- CRP and ESR
- Full blood count and ferritin
- Stool culture and C. difficile to exclude infection
- 25-hydroxyvitamin D
When to See a Doctor
Seek urgent care for more than six bloody stools daily with fever, rapid heart rate or abdominal distension, which may indicate severe colitis or toxic megacolon. See your team promptly for any flare with new blood, weight loss, or symptoms not responding to usual treatment within a few days.
Supplements Studied For This
Curcumin
Worth discussing as an add-on to mesalazine in mild to moderate disease. Evidence is add-on only — it has never been tested as monotherapy against standard care.
Probiotics
A reasonable add-on to mesalazine in mild to moderate disease, and genuinely effective for pouchitis prevention. Not a replacement for maintenance therapy.
Vitamin D
Correct a documented deficiency for bone and general health. Do not expect it to change disease activity.
Diet & Lifestyle
Suggested Pattern
No diet induces remission. During flares a lower-residue approach reduces symptom burden temporarily; in remission a varied fibre-containing diet is appropriate. The Mediterranean pattern is a reasonable default, and exclusive enteral nutrition is a Crohn disease therapy, not a UC one.
Supporting Research
Herbal Medicines for the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
First multicenter study of modified release phosphatidylcholine LT-02 in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses
Andrographis paniculata extract (HMPL-004) for active ulcerative colitis
Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine
Frequently Asked Questions
Who It Affects
Ulcerative colitis affects roughly 250 per 100,000 people in Western countries, with peak onset between ages 15 and 30 and a second smaller peak after 60.
Quick Facts
- •Inflammation is continuous from the rectum, unlike the patchy pattern in Crohn disease
- •Mesalazine adherence reduces relapse and lowers colorectal cancer risk
- •Multi-strain probiotics have randomised evidence in mild-moderate UC and pouchitis
- •Colonoscopic surveillance typically starts eight years after diagnosis
Lifestyle Tips
- •Keep taking maintenance therapy during remission — stopping is the commonest cause of relapse
- •Avoid NSAIDs, which can trigger flares
- •Have iron status checked regularly; deficiency is common even without visible bleeding
- •Keep vaccinations up to date before starting immunosuppressive therapy
- •Attend surveillance colonoscopy appointments once due
- •Track flare patterns rather than eliminating foods indiscriminately
Related Topics
My Notes
Sign in to add personal notes
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.